Rudy S Suidan1, Mario M Leitao2, Oliver Zivanovic2, Ginger J Gardner2, Kara C Long Roche1, Yukio Sonoda2, Douglas A Levine2, Elizabeth L Jewell2, Carol L Brown2, Nadeem R Abu-Rustum2, Mary E Charlson3, Dennis S Chi4. 1. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. 3. Division of Clinical Epidemiology and Evaluative Sciences Research, Weill Cornell Medical College, New York, NY, USA. 4. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: gynbreast@mskcc.org.
Abstract
OBJECTIVE: To assess the ability of the Age-Adjusted Charlson Comorbidity Index (ACCI) to predict perioperative complications and survival in patients undergoing primary debulking for advanced epithelial ovarian cancer (EOC). METHODS: Data were analyzed for all patients with stage IIIB-IV EOC who underwent primary cytoreduction from 1/2001-1/2010 at our institution. Patients were divided into 3 groups based on an ACCI of 0-1, 2-3, and ≥4. Clinical and survival outcomes were assessed and compared. RESULTS: We identified 567 patients; 199 (35%) had an ACCI of 0-1, 271 (48%) had an ACCI of 2-3, and 97 (17%) had an ACCI of ≥4. The ACCI was significantly associated with the rate of complete gross resection (0-1=44%, 2-3=32%, and ≥4=32%; p=0.02), but was not associated with the rate of minor (47% vs 47% vs 43%, p=0.84) or major (18% vs 19% vs 16%, p=0.8) complications. The ACCI was also significantly associated with progression-free (PFS) and overall survival (OS). Median PFS for patients with an ACCI of 0-1, 2-3, and ≥4 was 20.3, 16, and 15.4 months, respectively (p=0.02). Median OS for patients with an ACCI of 0-1, 2-3, and ≥4 was 65.3, 49.9, and 42.3 months, respectively (p<0.001). On multivariate analysis, the ACCI remained a significant prognostic factor for both PFS (p=0.02) and OS (p<0.001). CONCLUSIONS: The ACCI was not associated with perioperative complications in patients undergoing primary cytoreduction for advanced EOC, but was a significant predictor of PFS and OS. Prospective clinical trials in ovarian cancer should consider stratifying for an age-comorbidity covariate.
OBJECTIVE: To assess the ability of the Age-Adjusted Charlson Comorbidity Index (ACCI) to predict perioperative complications and survival in patients undergoing primary debulking for advanced epithelial ovarian cancer (EOC). METHODS: Data were analyzed for all patients with stage IIIB-IV EOC who underwent primary cytoreduction from 1/2001-1/2010 at our institution. Patients were divided into 3 groups based on an ACCI of 0-1, 2-3, and ≥4. Clinical and survival outcomes were assessed and compared. RESULTS: We identified 567 patients; 199 (35%) had an ACCI of 0-1, 271 (48%) had an ACCI of 2-3, and 97 (17%) had an ACCI of ≥4. The ACCI was significantly associated with the rate of complete gross resection (0-1=44%, 2-3=32%, and ≥4=32%; p=0.02), but was not associated with the rate of minor (47% vs 47% vs 43%, p=0.84) or major (18% vs 19% vs 16%, p=0.8) complications. The ACCI was also significantly associated with progression-free (PFS) and overall survival (OS). Median PFS for patients with an ACCI of 0-1, 2-3, and ≥4 was 20.3, 16, and 15.4 months, respectively (p=0.02). Median OS for patients with an ACCI of 0-1, 2-3, and ≥4 was 65.3, 49.9, and 42.3 months, respectively (p<0.001). On multivariate analysis, the ACCI remained a significant prognostic factor for both PFS (p=0.02) and OS (p<0.001). CONCLUSIONS: The ACCI was not associated with perioperative complications in patients undergoing primary cytoreduction for advanced EOC, but was a significant predictor of PFS and OS. Prospective clinical trials in ovarian cancer should consider stratifying for an age-comorbidity covariate.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Jason D Wright; Sharyn N Lewin; Israel Deutsch; William M Burke; Xuming Sun; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman Journal: Gynecol Oncol Date: 2011-09-28 Impact factor: 5.482
Authors: Rachel M Clark; Malinda S Lee; J Alejandro Rauh-Hain; Tracilyn Hall; David M Boruta; Marcela G del Carmen; Annekathryn Goodman; John O Schorge; Whitfield B Growdon Journal: Gynecol Oncol Date: 2014-12-02 Impact factor: 5.482
Authors: M Markman; J L Lewis; P Saigo; T Hakes; S Rubin; W Jones; B Reichman; J Curtin; R Barakat; L Almadrones Journal: Gynecol Oncol Date: 1993-05 Impact factor: 5.482
Authors: Tomi F Akinyemiju; Gurudatta Naik; Kemi Ogunsina; Daniel T Dibaba; Neomi Vin-Raviv Journal: Cancer Causes Control Date: 2018-02-10 Impact factor: 2.506
Authors: Stephanie Cham; Ling Chen; Caryn M St Clair; June Y Hou; Ana I Tergas; Alexander Melamed; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright Journal: Am J Obstet Gynecol Date: 2019-02-13 Impact factor: 8.661
Authors: William K Oelsner; Stephen M Engstrom; Michael A Benvenuti; Thomas J An; Richard A Jacobson; Gregory G Polkowski; Jonathan G Schoenecker Journal: J Arthroplasty Date: 2016-07-15 Impact factor: 4.757
Authors: Pratibha S Binder; Jeffrey F Peipert; D Kallogjeri; Rebecca A Brooks; L Stewart Massad; David G Mutch; Matthew A Powell; Premal H Thaker; Carolyn K McCourt Journal: Am J Obstet Gynecol Date: 2016-07-22 Impact factor: 8.661
Authors: Jill H Tseng; Rudy S Suidan; Oliver Zivanovic; Ginger J Gardner; Yukio Sonoda; Douglas A Levine; Nadeem R Abu-Rustum; William P Tew; Dennis S Chi; Kara Long Roche Journal: Gynecol Oncol Date: 2016-06-04 Impact factor: 5.482
Authors: Ying L Liu; Qin C Zhou; Alexia Iasonos; Olga T Filippova; Dennis S Chi; Oliver Zivanovic; Yukio Sonoda; Ginger Gardner; Vance Broach; Roisin OCearbhaill; Jason A Konner; Carol A Aghajanian; Kara Long; William Tew Journal: Int J Gynecol Cancer Date: 2020-06-09 Impact factor: 4.661